← Leaderboards
Rakesh Karmacharya
Mclean Hospital
$4,869,822
Attributed
$6,113,834
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,113,834 · 4
By mechanism
R01$5,212,814 · 3
K08$901,020 · 1
Top collaborators
- Stephen J Haggarty2 shared
- Paulo L Lizano1 shared
Most similar at Mclean Hospital
Same institution · by research overlap
- Dost Ongur$17,996,987
- Mei-Hua Hall$4,899,477
- Roscoe O. Brady$6,507,968
- Kathryn Eve Lewandowski$4,602,611
- Georgios Petrides$10,081,734
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingNeuronsPathway InteractionsMolecularSchizophreniaRodentPharmaceutical PreparationsImageBipolar DisorderBiologyBrainBasePsychiatryCell LinePlayNeurobiologyCellsPropertyFunctional DisorderInduced Pluripotent Stem CellAntipsychotic AgentsPsychotic DisordersMessenger RnaNovel Therapeutic Intervention
Grant awards (14)
Dysfunctional neurovascular interactions and neuroprogression in early-course psychosis: ex vivo investigation with patient-derived stem cells$836,344
R01 · FY2025 · MH · contact PI
Targeting Arc to Improve Cognitive Deficits in Psychotic Disorders$825,005
R01 · FY2025 · MH · contact PI
Targeting Arc to Improve Cognitive Deficits in Psychotic Disorders$826,675
R01 · FY2024 · MH · contact PI
Ex vivo signature of psychosis and treatment response in patient-derived neurons$544,958
R01 · FY2021 · MH · contact PI
Ex vivo signature of psychosis and treatment response in patient-derived neurons$544,958
R01 · FY2020 · MH · contact PI
Ex vivo signature of psychosis and treatment response in patient-derived neurons$544,958
R01 · FY2019 · MH · contact PI
Ex vivo signature of psychosis and treatment response in patient-derived neurons$544,958
R01 · FY2018 · MH · contact PI
Ex vivo signature of psychosis and treatment response in patient-derived neurons$544,958
R01 · FY2017 · MH · contact PI
Wnt/GSK3/beta Catenin Signaling as a Target for Treatment of Bipolar Disorder$180,252
K08 · FY2014 · MH · contact PI
Wnt/GSK3/beta Catenin Signaling as a Target for Treatment of Bipolar Disorder$180,252
K08 · FY2013 · MH · contact PI
Wnt/GSK3/beta Catenin Signaling as a Target for Treatment of Bipolar Disorder$180,252
K08 · FY2012 · MH · contact PI
Wnt/GSK3/beta Catenin Signaling as a Target for Treatment of Bipolar Disorder$91,755
K08 · FY2011 · MH · contact PI
Wnt/GSK3/beta Catenin Signaling as a Target for Treatment of Bipolar Disorder$88,497
K08 · FY2011 · MH · contact PI
Wnt/GSK3/beta Catenin Signaling as a Target for Treatment of Bipolar Disorder$180,012
K08 · FY2010 · MH · contact PI